Although we previously determined that CD74 exclusively associates with activation-resistant FAS through analysis of primary cell apoptosis in the patients with non-Hodgkin’s lymphoma [22], these new findings were observed in TNBC cells and are highly significant to target CD74/FAS and CD74/AKT axes with novel approaches to inhibit aggressive breast cancer cells and improve the outcome of patients. This evidence concerns the gene CD74 and breast carcinoma.